L-163,491

L-163,491
Legal status
Legal status
  • US: Investigational drug
Identifiers
  • Butyl (4'-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5-(3-methoxybenzyl)-[1,1'-biphenyl]-2-yl)sulfonylcarbamate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC36H40N4O5S
Molar mass640.80 g·mol−1
3D model (JSmol)
  • CCCCOC(=O)NS(=O)(=O)C1=C(C=C(C=C1)CC2=CC(=CC=C2)OC)C3=CC=C(C=C3)CN4C(=NC5=C4N=C(C=C5C)C)CC
  • InChI=1S/C36H40N4O5S/c1-6-8-18-45-36(41)39-46(42,43)32-17-14-28(20-27-10-9-11-30(21-27)44-5)22-31(32)29-15-12-26(13-16-29)23-40-33(7-2)38-34-24(3)19-25(4)37-35(34)40/h9-17,19,21-22H,6-8,18,20,23H2,1-5H3,(H,39,41)
  • Key:SRCIRAKBWHTYIX-UHFFFAOYSA-N

L-163,491 is an experimental drug which acts as a partial agonist of angiotensin II receptor type 1, and with lower affinity as an agonist of angiotensin II receptor type 2, mimicking the action of angiotensin II.[1] Its practical applications to date have been limited to scientific research into the function of the angiotensin receptor system,[2] but it has been suggested as a potential therapeutic agent for the treatment of inflammation of the lungs associated with certain viral diseases such as COVID-19.[3][4]

References

  1. ^ De Witt BJ, Garrison EA, Champion HC, Kadowitz PJ (September 2000). "L-163,491 is a partial angiotensin AT(1) receptor agonist in the hindquarters vascular bed of the cat". European Journal of Pharmacology. 404 (1–2): 213–9. doi:10.1016/s0014-2999(00)00612-9. PMID 10980281.
  2. ^ Alterman M (March 2010). "Development of selective non-peptide angiotensin II type 2 receptor agonists". Journal of the Renin-Angiotensin-Aldosterone System. 11 (1): 57–66. doi:10.1177/1470320309347790. PMID 19880657.
  3. ^ Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. (2020). "Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases". ACS Central Science. 6 (3): 315–331. doi:10.1021/acscentsci.0c00272. PMC 7094090. PMID 32226821.
  4. ^ Wu Y (February 2020). "Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury". Virologica Sinica. 35 (3): 256–258. doi:10.1007/s12250-020-00205-6. PMC 7091449. PMID 32034638.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.